Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact ...
A publication from Acta Pharmaceutica Sinica B discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a debilitating ...
Allostery can be defined as the regulation of protein function, structure and/or flexibility induced by the binding of a ligand or another protein, termed an effector, at a site away from the active ...
A team of scientists, led by Dr Steven West at the University of Exeter’s Living Systems Institute, have revealed a fresh insight into how genes are copied. The human genome - or the entire set of DNA ...
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, ...
Drug hunters have spent years cutting chemical keys to fit the most obvious biological locks: a protein’s active site, the spot where its natural substrate clicks in to turn it on or off. Walk into ...
Allostery refers to the binding of a metabolite at a site other than the chemically active site of a protein. The existence of allosteric sites on receptor molecules has expanded potential drug ...
Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback